CAJ | 학술논문

目的：探讨胸腺法新对晚期非小细胞肺癌（ NSCLC ）患者免疫功能的影响。方法 NSCLC患者100例随机分为2组，治疗组52例，对照组48例，2组均给予联合化疗，治疗组在此基础上加用胸腺法新皮下注射，治疗4个疗程后进行T细胞亚群联合测定，并观察合并感染发生情况。结果（1）免疫功能变化比较：对照组治疗后CD4＋及CD8＋变化不明显（ P ＞0．05），CD4＋/CD8＋比值降低（ P ＜0．05）；治疗组CD4＋及CD4＋/CD8＋升高（ P ＜0．05），CD8＋变化不明显（ P ＞0．05）；治疗组CD4＋及CD4＋/CD8＋高于对照组（ P ＜0．05）。（2）感染发生率比较：治疗组发生感染性疾病16例（30．77％），对照组发生感染性疾病18例（37．50％），2组差异有统计学意义（ t ＝2．021， P ＜0．05）。（3）生存时间比较：治疗组中位生存时间长于对照组（12．9个月vs．11．9个月， P ＜0．05）。结论胸腺法新能降低晚期非小细胞肺癌患者的感染发生率，降低因合并感染而发生的病死率，提高患者的中位生存时间。
목적：탐토흉선법신대만기비소세포폐암（ NSCLC ）환자면역공능적영향。방법 NSCLC환자100례수궤분위2조，치료조52례，대조조48례，2조균급여연합화료，치료조재차기출상가용흉선법신피하주사，치료4개료정후진행T세포아군연합측정，병관찰합병감염발생정황。결과（1）면역공능변화비교：대조조치료후CD4＋급CD8＋변화불명현（ P ＞0．05），CD4＋/CD8＋비치강저（ P ＜0．05）；치료조CD4＋급CD4＋/CD8＋승고（ P ＜0．05），CD8＋변화불명현（ P ＞0．05）；치료조CD4＋급CD4＋/CD8＋고우대조조（ P ＜0．05）。（2）감염발생솔비교：치료조발생감염성질병16례（30．77％），대조조발생감염성질병18례（37．50％），2조차이유통계학의의（ t ＝2．021， P ＜0．05）。（3）생존시간비교：치료조중위생존시간장우대조조（12．9개월vs．11．9개월， P ＜0．05）。결론흉선법신능강저만기비소세포폐암환자적감염발생솔，강저인합병감염이발생적병사솔，제고환자적중위생존시간。
Objective To investigate the effect of thymalfasin on the immune function of patients with advanced non -small cell lung cancer (NSCLC ).Methods 100 NSCLC patients were randomly divided into 2 groups, 52 cases in the treat-ment group , 48 cases in the control group , the 2 groups were given combined chemotherapy , the treatment group also used of thymalfasin subcutaneous injection , T cell subsets joint was measured after 4 courses of treatment , and to observe the occur-rence of the infection.Results (1) Compared the change of immune function: the control group after treatment , CD4+and CD8+did not change significantly ( P >0.05),CD4+/CD8+ratio decreased ( P <0.05), in treatment group,CD 4+and CD 4+/CD8+increased ( P <0.05), CD8+did not change significantly ( P >0.05), in the treatment group, CD4+and CD4+/CD8+higher than that of control group ( P <0.05).(2) The incidence of infection:the treatment group had 16 cases of infectious diseases (30.77%), the control group had 18 cases of infectious diseases (37.50%), with a significant difference between the 2 groups ( t =2.021, P <0.05).(3) The survival time: in the treatment group, the median survival time was longer than that of the control group ( 12.9 months vs.11.9 months, P <0.05).Conclusion Thymalfasin could reduce the inci-dence of infection in advanced non-small cell lung cancer patients , as well to reduce mortality due to infection rate , and im-prove the median survival time of patients .